Download PDF

1. Company Snapshot

1.a. Company Description

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States.The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components.


The company is based in Redwood City, California.

Show Full description

1.b. Last Insights on BTCY

Here is a 90-word analysis of the positive drivers behind Biotricity, Inc.'s recent stock performance: Biotricity's recent strong performance is driven by its achievement of cash flow breakeven and record revenue growth of 11% in Q3 2025. The company delivered record margins, revenues, and cash flows, with 21.7% year-over-year sales growth. Additionally, Biotricity achieved positive free cash flow, a major milestone towards profitability. The company has also produced its largest inventory in history to meet accelerated demand, and partnered with B-Secur to launch a comprehensive device-neutral ambulatory cardiac monitoring platform, further enhancing its growth prospects.

1.c. Company Highlights

2. Biotricity's Path to Profitability Gains Momentum

Biotricity reported a 19% year-over-year revenue increase to $3.9 million, driven by the adoption of its Technology-as-a-Service subscription model and the popularity of its FDA-cleared cardiac monitoring devices, particularly the next-gen Biocore Pro. The company achieved EBITDA of $373,000, or $0.14 per share, and an actual EPS loss of -$0.03, beating estimates of -$0.08. The revenue growth and EBITDA achievement underscore Biotricity's strategic initiatives and operational efficiency. With a current P/S Ratio of 0.88, the market seems to have a moderate expectation of the company's revenue growth, which is expected to be 15.3% next year.

Publication Date: Nov -29

📋 Highlights
  • Revenue Growth:: Q2 revenue rose 19% to $3.9M, driven by Biocore Pro adoption and subscription model.
  • Profitability Proximity:: Achieved $373K EBITDA ($0.14/share), signaling breakeven potential and cusp of profitability.
  • Product Pipeline:: Developing multiparameter cardiac monitor and finalizing Biocore Pro 2 (FDA filing expected Q1 2027).
  • Commercial Expansion:: Scaling sales team, investing profits into market share growth and top-line acceleration.
  • Pilot Programs:: Expanded Biocore Pro sales and launched major cardiac monitoring pilots with hospitals/clinics.

Operational Highlights and Future Plans

Biotricity is developing a multiparameter cardiac monitor and finalizing Biocore Pro 2, its next-generation cardiac monitor, expected to be filed for FDA clearance by the end of Q1 next year. The company has also expanded sales of Biocore Pro and launched major cardiac monitoring pilot programs with several hospital networks and clinics. As Dr. Waqaas Al-Siddiq mentioned, the focus is on "innovation, strategic execution, and operational efficiency" to drive growth and scalability. The expansion into other verticals that fit naturally with the core business is also a promising development initiative.

Valuation and Expectations

The current EV/EBITDA ratio of -73.98 indicates that the market has high expectations for future EBITDA growth, which is expected given the company's path to profitability. The ROE of 14.6% and ROIC of 11.94% suggest that Biotricity is generating value for its shareholders. With the P/B Ratio at -0.35, it indicates that the book value is not a significant component of the company's valuation, likely due to its intangible assets and growth prospects. As Biotricity continues to invest its profits into commercial expansion, the expectation is that revenue will continue to increase, and margins will be maintained, driving the company towards profitability.

Outlook

Biotricity's confidence in being on the cusp of profitability is backed by its strategic initiatives and operational efficiency. The company's focus on scaling the business, expanding its commercial team, and investing in commercial expansion to drive growth and market share is expected to yield positive results. As the company continues to innovate and execute its strategy, the outlook remains positive, with expectations of increasing revenues and maintained margins.

3. NewsRoom

Card image cap

Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript

Nov -14

Source: seekingalpha.com

Card image cap

Biotricity Inc. (BTCY) Reports Q2 Loss, Lags Revenue Estimates

Nov -14

Source: zacks.com

Card image cap

Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026

Nov -14

Source: globenewswire.com

Card image cap

Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th

Nov -07

Source: globenewswire.com

Card image cap

Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users

Sep -09

Source: prnewswire.com

Card image cap

Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform

Sep -03

Source: globenewswire.com

Card image cap

Are Medical Stocks Lagging Biotricity (BTCY) This Year?

Aug -19

Source: zacks.com

Card image cap

Biotricity (BTCY) Upgraded to Buy: Here's Why

Aug -15

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (13.55%)

6. Segments

Technology Fees

Expected Growth: 14.07%

Biotricity's 14.07% growth in Technology Fees is driven by increasing adoption of its remote patient monitoring solutions, expansion into new healthcare verticals, and growing demand for telemedicine services. Additionally, the company's investments in AI-powered analytics and IoT-enabled devices have enhanced its value proposition, leading to higher revenue from technology licensing and subscription fees.

Device

Expected Growth: 8.9%

Biotricity's device growth is driven by increasing demand for remote patient monitoring, advancements in AI-powered diagnostics, and expanding healthcare access. The company's focus on cardiovascular and respiratory disease management, coupled with its innovative technology and strategic partnerships, have contributed to its 8.9% growth.

7. Detailed Products

Bioflux

A mobile cardiac telemetry device that provides real-time monitoring of a patient's heart rhythm

Biotres

A suite of software solutions for remote patient monitoring and data analytics

Biocare

A range of wearable devices for remote patient monitoring, including ECG, blood glucose, and blood pressure monitoring

Biotricity Wellness

A comprehensive wellness program that includes health coaching, nutrition planning, and stress management

8. Biotricity, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Biotricity, Inc. faces moderate threat from substitutes due to the presence of alternative medical devices and services.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of Biotricity's products and services.

Bargaining Power Of Suppliers

Suppliers have moderate bargaining power due to the availability of alternative suppliers and the company's dependence on a few key suppliers.

Threat Of New Entrants

The medical device industry is highly competitive, and new entrants can easily enter the market, posing a significant threat to Biotricity, Inc.

Intensity Of Rivalry

The medical device industry is highly competitive, and rivalry among existing players is intense, posing a significant threat to Biotricity, Inc.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -6532.53%
Debt Cost 11.70%
Equity Weight 6632.53%
Equity Cost 11.70%
WACC 11.70%
Leverage -98.49%

11. Quality Control: Biotricity, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Biotricity

A-Score: 5.2/10

Value: 9.4

Growth: 5.6

Quality: 6.0

Yield: 0.0

Momentum: 10.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Electromed

A-Score: 4.8/10

Value: 2.9

Growth: 8.7

Quality: 7.8

Yield: 0.0

Momentum: 6.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Tactile Systems Technology

A-Score: 4.5/10

Value: 5.7

Growth: 7.7

Quality: 7.0

Yield: 0.0

Momentum: 4.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Quipt Home Medical

A-Score: 3.8/10

Value: 8.7

Growth: 6.7

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Talis Biomedical

A-Score: 3.7/10

Value: 8.2

Growth: 4.6

Quality: 4.4

Yield: 0.0

Momentum: 3.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Myomo

A-Score: 2.9/10

Value: 8.0

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.46$

Current Price

0.46$

Potential

-0.00%

Expected Cash-Flows